LivaNova Receives FDA Approvals for SenTiva Device and Next-Generation VNS Therapy Programming System for Treatment of Epilepsy
10 October 2017
LivaNova PLC, a market-leading medical technology company, today announced it received U.S. Food and Drug Administration (“FDA”) approvals for its latest Vagus Nerve Stimulation Therapy
